BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
So I don't know if this is just a little bit of noise from the... I think they were very similar in terms of the 12-month CR rate, but I would have thought that it would have been a little bit better with the combination, and it wasn't. The TAR-200 did just as well as monotherapy in terms of the 12-month CR.
0
💬
0
Comments
Log in to comment.
There are no comments yet.